After Wegovy: What Happens to Your Weight and What Comes Next

Why weight often returns after stopping, and what the evidence says

The appetite-suppressing effect of semaglutide depends on the medicine being active in your system. Once you stop, GLP-1 receptor activity returns to baseline, hunger signals resume, and the biological drive to regain weight reasserts itself. This isn't unique to Wegovy: it's the same pattern seen across most effective weight-loss medicines, and it's one reason obesity is now framed as a chronic condition rather than something you treat once and consider resolved.

The STEP 1 extension study followed participants for a year after they stopped semaglutide 2.4mg. On average, about two-thirds of the weight lost during treatment had returned by week 120, and most cardiometabolic improvements (blood pressure, cholesterol, blood glucose markers) also reversed proportionally. The NHS semaglutide medicines page notes that treatment is intended to be used alongside lasting dietary and activity changes precisely because the medicine supports, rather than replaces, those habits.

None of this means Wegovy failed. It means the question of what happens after is part of the treatment plan, not an afterthought. If you're curious about the early signs of progress and want to understand what to expect, our page on what Wegovy typically looks like after the first month gives a grounded picture of how the medicine works over that initial period. If you started Wegovy privately and are thinking about whether to continue, switch, or stop, that thinking is worth doing with a prescriber rather than in a gap between prescriptions. More on what continued support through a private route looks like is covered on our life after Wegovy page.

Continuing semaglutide: when it stays the right choice

For many people, the answer after Wegovy is simply more Wegovy, or a structured plan for gradually stepping down under clinical supervision. If treatment has been effective and well-tolerated, and your health profile still fits the licensed criteria, there's no clinical reason to change medicines for the sake of change.

Under NICE guidance (TA875), NHS use of semaglutide for weight management is capped at two years within a specialist service. Private prescribing follows the licensed indication rather than that time limit specifically, but a good prescriber will review the benefit-to-risk picture at each repeat, not just issue the same prescription indefinitely. If you've been on Wegovy for a long time without meaningful ongoing weight loss, that review conversation matters.

Access is a practical factor too. Wegovy supply has been inconsistent at times, and if you've moved between providers or had a gap, a new prescriber will want to understand your treatment history before continuing or adjusting your dose. The Wegovy treatment page has more on how the dose schedule works in practice. For a straightforward cost comparison across providers, the Wegovy cost page is a useful reference before you commit to a route.

Switching to tirzepatide: who it suits and what the evidence shows

Tirzepatide (Mounjaro) is the alternative most people researching this topic end up considering. It works differently from semaglutide: where Wegovy activates one receptor pathway (GLP-1), tirzepatide activates two, both GIP and GLP-1. In practice, that difference translates to greater average weight loss in the clinical evidence to date.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4mg over 72 weeks in adults with obesity. Tirzepatide produced greater average weight reduction. NICE has appraised tirzepatide in TA1026, recommending it for adults with a BMI of 35 or above and at least one weight-related comorbidity, with lower thresholds applied for certain ethnic backgrounds under UK guidance.

Switching isn't automatic. A prescriber will consider whether tirzepatide is clinically appropriate given your history, any conditions the prescriber needs to account for, and how you got on with semaglutide. Side-effect profiles overlap but aren't identical. If you're curious about early experience on tirzepatide (what the first weeks feel like and what to expect at each dose) the first four weeks on a GLP-1 medicine page gives a grounded picture of what that adjustment period looks like. Our weight-loss treatment overview also maps out the full range of options currently available.

Managing without pharmacological support: realistic expectations

Some people stop Wegovy because they want to, not because they have to. Perhaps you've reached a weight your prescriber and you are both satisfied with, your lifestyle changes feel established, and you'd rather see whether you can maintain without medicine. That's a legitimate choice, and it deserves an honest picture of what it typically involves.

The evidence suggests that maintaining weight loss after stopping a GLP-1 medicine requires sustained attention to both dietary intake and physical activity, not a rigid plan, but an ongoing one. People who fare best tend to have built habits during treatment rather than relying solely on reduced appetite. If weight does start to return and you want to understand your options at that point, weight loss after Wegovy covers the clinical reality in more detail.

There's no shame in deciding you need ongoing support. Obesity is a chronic condition shaped by genetics, hormones and environment, not a willpower problem. If you'd like a prescriber to review your situation and discuss what makes sense for you now, check your eligibility with our clinical team. Our prescribers review each consultation personally; there's no algorithm reading your answers.